Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C514S418000, C514S422000, C514S426000
Reexamination Certificate
active
06878733
ABSTRACT:
The present invention features formulations of indolinones which compounds are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term “ionizable substituted indolinone” includes pyrrole substituted 2-indolinones which, in addition to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compound, are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group. The formulations and the compounds themselves are useful for the treatment of protein kinase related disorders as discussed herein.
REFERENCES:
patent: 4002749 (1977-01-01), Rovnyak et al.
patent: 4053613 (1977-10-01), Rovnyak et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5786488 (1998-07-01), Tang et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5840745 (1998-11-01), Buzzetti et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 0 252 731 (1988-01-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 566 226 (1993-10-01), None
patent: 0 934 931 (1999-08-01), None
patent: 0 934 931 (1999-08-01), None
patent: 1 599 772 (1970-07-01), None
patent: 9113055 (1991-09-01), None
patent: 9115495 (1991-10-01), None
patent: 9207830 (1992-05-01), None
patent: 9220642 (1992-11-01), None
patent: 9221660 (1992-12-01), None
patent: 9301182 (1993-01-01), None
patent: 9323040 (1993-11-01), None
patent: 9403427 (1994-02-01), None
patent: 9410202 (1994-05-01), None
patent: 9414808 (1994-07-01), None
patent: 9501349 (1995-01-01), None
patent: 9514667 (1995-06-01), None
patent: 9524190 (1995-09-01), None
patent: 9600226 (1996-01-01), None
patent: 9616964 (1996-06-01), None
patent: 9622976 (1996-08-01), None
patent: 9632380 (1996-10-01), None
patent: 9640116 (1996-12-01), None
patent: 9807695 (1998-02-01), None
patent: 9807835 (1998-02-01), None
patent: 9824432 (1998-06-01), None
patent: 9838984 (1998-09-01), None
patent: 9845708 (1998-10-01), None
patent: 9850356 (1998-11-01), None
patent: 9856376 (1998-12-01), None
patent: 9910325 (1999-03-01), None
patent: 9919325 (1999-04-01), None
patent: 9948868 (1999-09-01), None
patent: 9961422 (1999-12-01), None
patent: 0008202 (2000-02-01), None
patent: 0035908 (2000-06-01), None
patent: 0038519 (2000-07-01), None
patent: 0056709 (2000-09-01), None
Stein, Jay, Editor-in-Chief, Internal Medicine, 4thEdition, Chapters 71-72, pp. 699-715, 1994.*
Akbasak and Sunar-Akbasak., “Oncogenes: cause or consequence in the development of glial tumors,”J. Neurol. Sci. 111:119-133 (1992).
Andreani et al., “Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo2,1-bithiazolylmethylene)-2-indolinones,”Eur. J. Med. Chem. 32:919-924 (1997) ©Elsevier, Paris.
Andreani et al., “In vivo cardiotonic activity of pyridylmethylene-2-indolinones”Arzneimittel-Forschung Drug Research48(II): 727-729 (1998).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones,”Eur. J. Med. Chem. 25(2):187-190 (1990).
Arteaga et al., “Blockade of the Type 1 Somatomedin Receptor Inhibits Growth of Human Breast Cancer Bells in Athymic Mice,”J. Clin. Invest. 84:1418-1423 (1989) ©The American Society for Clinical Investigation, Inc.
Arvidsson et al., “Try-716 in the Platelet-Derived-Growth-Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation,”Molecular and Cellular Biology14(10):6715-6726 (1994) ©The American Society for Microbiology.
Baserga, “Oncogenes and the Strategy of Growth Factors,”Cell79:927-93 (1994) ©Cell Press.
Baserga, “The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?”Cancer Research55:249-252 (1995).
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”FASEB J. 6:3403-3409 (1992).
Bolen, “Nonreceptor tyrosine protein kinases,”Oncogene8:2025-2031 (1993) ©MacMillan Press Ltd.
Bonner et al., “Structure and Biological Activity of Human Homologs of a raf-mil Oncogene,”Molecular and Cellular Biology5:1400-1407 (1985) ©The American Society for Microbiology.
Cance et al., “Novel Protein Kinases Expressed in Human Breast Cancer,”Int. J. Cancer54:571-577 (1993) ©Wiley-Liss, Inc.
Carpenedo et al., “Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs”Analytical Biochemistry244:74-79 (1997) ©Academic Press, Inc.
Chen et al., “Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron”Chinese Journal of Physiology40(3):149-156 (1997).
Claesson-Welsh, “Signal Transduction by the PDGF Receptor,”Progress in Growth Factor Research5:37-54 (1994) ©Elsevier Science Ltd.
Coppola et al., “A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,”Molecular and Cellular Biology14:4588-4595 (1994) ©The American Society for Microbiology.
Damiani et al., “Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals,”Biochemical Pharmacology48(6):1155-1161 (1994) ©Elsevier Science Ltd.
Davis et al., “Synthesis and microbiological properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds,”Journal of Medicinal Chemistry16(9):1043-1045 (1973) ©American Chemical Society.
De Vries et al., “The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science255:989-991, 1991.
Decker and Lohmann-Matthes, “A quick and simple method for the quantitation of lactate deydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,”J. Immunol. Methods15:61-69 (1988) ©Elsevier.
Decodts et al., “Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams,”Eur. J. Med. Chem.—Chim. Ther., 18(2):107-111 (1983).
Dickson et al., “Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer,”Cancer Treatment Res. 61:249-273 (1992) ©Kluwer Academic Publishers.
Fantl et al., “Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways,”Cell69:413-423 (1992) ©Cell Press.
Fendly et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2-neu Gene product,”Cancer Research50:1550-1558 (1990) (mistakenly referred to as Fendley).
Ferrara and Henzel, “Pituitary Fillicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,”Biochemical and Biophysical Research Communications161:851-858 (1989) ©Academic Press, Inc.
Fingl and Woodbury, “Chapter 1—General Principles,” inThe Pharmacological Basis of Therapeutics5thedition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) ©MacMillam Publishing Co., Inc.
Floege et al., “Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis,”Kidney International43:369-380 (1993) ©International Society of Nephrology.
Floege et al., “Factors involoved in the
Koparkar Arun
Shenoy Narmada
Sorasuchart Waranush
Burrous Beth A.
Foley & Lardner
Jones Dwayne C.
Sugen Inc.
LandOfFree
Formulations for pharmaceutical agents ionizable as free... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations for pharmaceutical agents ionizable as free..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations for pharmaceutical agents ionizable as free... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3391240